1. Lozier JN, Kessler CM. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editor. Clinicl aspects and therapy of hemophilia. Hematology, Basic Principles and Practice 2005;4th ed. Philadelphia: Elsevier Churchill Livinstone. 2047-2069.
2. World Federation of Hemophilia. Treatment of Bleeding in Hemophilia. Guidelines for the management of Hemophilia 2005;Montreal: World Federation of Hemophilia. 37-44.
3. World Federation of Hemophilia. Plasma Factor Level and Duration of Administration. Guidelines for the management of Hemophilia 2005;Montreal: World Federation of Hemophilia. 45-46.
4. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in Hemophilia: Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
5. Feinstein DI. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editor. Inhibitors in hemophilia. Hematology, Basic Principles and Practice 2005;4th ed. Philadelphia: Elsevier Churchill Livinstone. 2071-2080.
6. Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006;133:591-605.
7. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007;109:546-551.